Abstract
The U.S. Multiple Myeloma Market is a rapidly progressing field that is set to generate over $3 billion in revenue in the coming years. The market has witnessed unprecedented growth with the launch of three new drugs. The dynamics of this market are changing rapidly and the forecast through 2013 highlights the major changes. This study includes patient forecasts, pipeline analysis and individual product revenue forecasts.
Table of Contents
1 EXECUTIVE SUMMARY
- Executive Summary
- Executive Summary
2 MARKET INTRODUCTION
- Research Scope and Methodology
- Scope and Segmentation
- Research Methodology
- Blood Cancer Overview
- Blood Cancer Biology
- Blood Cancer Definitions
- Multiple Myeloma Overview
- Etiology
- Staging and Prognostic Factors
- Treatment Overview
- Patient Forecasts
- Prevalence
- Incidence
- Mortality
- Staging
- General Market Trends
- Industry Challenges and Strategies
- Market Drivers
3 PRODUCT AND PIPELINE ANALYSIS
- Approved Product Analysis
- Chemotherapy Product Analysis
- Steroid Product Analysis
- Interferon Product Analysis
- Immunomodulatory Product Analysis
- Pipeline Analysis
- Chemotherapy Pipeline Analysis
- Targeted Therapy Late Stage Pipeline Analysis
- Targeted Therapy Early Stage Pipeline Analysis
- Supportive Product Pipeline
4 COMPETITIVE ANALYSIS
- Introduction
- Treatment Trends
- Market Engineering Measurements
- Common Drug Regimens
- Drug Prices
- Market Revenue Forecasts
- Total Market Revenue Forecasts
- First-line HSCT Eligible Revenue Forecasts
- First-line HSCT Non-Eligible Revenue Forecasts
- Second-line Revenue Forecasts
- Third-line+ Revenue Forecasts
- Market Share Analysis
- Product Revenue Forecasts
- Alkeran
- Doxil
- Revlimid
- Thalomid
- Velcade
- Tanespimycin
- ZIO-101
- Perifosine
5 APPENDIX
- Decision Support Databases
- Physicians
- Government Healthcare Expenditure
- Private Healthcare Expenditure
- Pharmaceutical R&D Expenditure
- Percent Pharmaceutical R&D Expenditure
